ReviewPediatric nephrology (Berlin, Germany)2016
Why are kids with lupus at an increased risk of cardiovascular disease?
Review in Pediatric nephrology (Berlin, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Management and outcomes in children with lupus nephritis in the developing countries.Pediatric nephrology (Berlin, Germany) · 2023Pooled it
- Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study.PloS one · 2019Trial
- Do we really need cyclophosphamide for lupus nephritis?Pediatric nephrology (Berlin, Germany) · 2024Article
- Article
- The potential role of Colchicine in preventing coronary vascular disease in childhood-onset lupus: a new view on an old drug.Pediatric rheumatology online journal · 2021Review
- Juvenile systemic lupus erythematosus presenting as pancarditis.Pediatric rheumatology online journal · 2019Article
- Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2018Article
- Differential gene expression profiles in peripheral blood in Northeast Chinese Han people with acute myocardial infarction.Genetics and molecular biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile-onset systemic lupus erythematosus (SLE) is an aggressive multisystem autoimmune disease. Despite improvements in outcomes for adult patients, children with SLE continue to have a lower life expectancy than adults with SLE, with more aggressive disease, a higher incidence of lupus nephritis and there is an emerging awareness of their increased risk of cardiovascular disease (CVD). In this review, we discuss the evidence for an increased risk of CVD in SLE, its pathogenesis, and the clinical approach to its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.